Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021

After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, reduced surgi...

Descripción completa

Detalles Bibliográficos
Autores principales: Burton, Elizabeth M., Amaria, Rodabe N., Cascone, Tina, Chalabi, Myriam, Gross, Neil D., Mittendorf, Elizabeth A., Scolyer, Richard A., Sharma, Padmanee, Ascierto, Paolo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199148/
https://www.ncbi.nlm.nih.gov/pubmed/35706041
http://dx.doi.org/10.1186/s12967-022-03472-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199148/
https://www.ncbi.nlm.nih.gov/pubmed/35706041
http://dx.doi.org/10.1186/s12967-022-03472-x

Ejemplares similares